- Home
- SDST vs IFRX Comparison
SDST vs IFRX Comparison
Compare SDST & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDST
- IFRX
- Stock Information
- Founded
- SDST 2022
- IFRX 2007
- Country
- SDST United States
- IFRX Germany
- Employees
- SDST N/A
- IFRX N/A
- Industry
- SDST Blank Checks
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- SDST Finance
- IFRX Health Care
- Exchange
- SDST Nasdaq
- IFRX Nasdaq
- Market Cap
- SDST 176.9M
- IFRX 143.7M
- IPO Year
- SDST N/A
- IFRX 2017
- Fundamental
- Price
- SDST $2.04
- IFRX $2.54
- Analyst Decision
- SDST Strong Buy
- IFRX Strong Buy
- Analyst Count
- SDST 1
- IFRX 1
- Target Price
- SDST $13.00
- IFRX $8.00
- AVG Volume (30 Days)
- SDST 112.5K
- IFRX 174.5K
- Earning Date
- SDST 02-15-2025
- IFRX 11-08-2024
- Dividend Yield
- SDST N/A
- IFRX N/A
- EPS Growth
- SDST N/A
- IFRX N/A
- EPS
- SDST N/A
- IFRX N/A
- Revenue
- SDST N/A
- IFRX $187,930.00
- Revenue This Year
- SDST N/A
- IFRX $392.79
- Revenue Next Year
- SDST N/A
- IFRX $156.76
- P/E Ratio
- SDST N/A
- IFRX N/A
- Revenue Growth
- SDST N/A
- IFRX 177.12
- 52 Week Low
- SDST $2.03
- IFRX $1.17
- 52 Week High
- SDST $28.38
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- SDST N/A
- IFRX 56.66
- Support Level
- SDST N/A
- IFRX $2.16
- Resistance Level
- SDST N/A
- IFRX $2.65
- Average True Range (ATR)
- SDST 0.00
- IFRX 0.24
- MACD
- SDST 0.00
- IFRX -0.01
- Stochastic Oscillator
- SDST 0.00
- IFRX 63.33
About SDST Stardust Power Inc. Common Stock
Stardust Power Inc is a development stage manufacturer of battery-grade lithium products deigned to supply the EV industry and helping to secure America's leadership in the energy transition. They enjoy a diversified supply of lithium from American brine sources.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.